secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001140361-24-025047
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed Q1 ARIKAYCE revenue $75.5M (+16%); TPIP PH-ILD shows strong clinical worsening signal
--------------------------------------------------------------------------------

- ARIKAYCE Q1 revenue $75.5M, up 16% YoY; net loss $157.1M ($1.06/share) vs $159.8M ($1.17) prior year.
- TPIP Phase 2 PH-ILD: 79.3% reached max 640µg dose; clinical worsening 10.3% vs 50% placebo (p=0.0164).
- TPIP Phase 2 PAH blinded: first 40 patients showed mean PVR reduction 19.9%, 6MWD +43 meters.
- Brensocatib ASPEN topline data expected latter part of Q2 2024; 2024 ARIKAYCE guidance $340M-$360M.
- Cash $595.7M at March 31, 2024; company plans Phase 3 for TPIP in PH-ILD in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036124025047/0001140361-24-025047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036124025047/ef20028736_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-025047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer